Nitric oxide in cardiac transplantation

Pharmacological Reports

Volumn 58, Issue SUPPL., 2006, Pages 145-152

  Diet, Wolfgang ^a   Bauer, Michael ^a   Podesser, Bruno K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Donor and recipient management; Heart transplantation; Nitric oxide

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE DONOR;

CRYOANESTHESIA; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGY; METABOLISM; ORGAN PRESERVATION; PATHOPHYSIOLOGY; REPERFUSION INJURY; REVIEW; STUNNED HEART MUSCLE; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; HEART TRANSPLANTATION; HUMANS; HYPOTHERMIA, INDUCED; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL STUNNING; NITRIC OXIDE; NITRIC OXIDE DONORS; ORGAN PRESERVATION;

EID: 38449107737     PISSN: 17341140     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Albrecht EW, Stegeman CA, Tiebosch AT, Tegzess AM, van Goor H: Expression of inducible and endothelial nitric oxide synthases, formation of peroxynitrite and reactive oxygen species in human chronic renal transplant failure. Am J Transplant, 2002, 2, 448–453.
2. Andrasi TB, Soos P, Bakos G, Stumpf N, Blazovics A, Hagl S, Szabo G.: L-arginine protects the mesenteric vascular circulation against cardiopulmonary bypass-induced vascular dysfunction. Surgery, 2003, 134, 72–79.
3. Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, Moriguchi J, Hamilton MA et al.: Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation, 2001, 72, 638–641.
4. Baue AE: The horror autotoxicus and multiple-organ failure. Arch Surg, 1992, 127, 1451–1462.
5. Bolli R: Mechanism of myocardial “stunning”. Circulation, 1990, 82, 723–738.
6. Bolli R: Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol, 2001, 33, 1897–1918.
7. Cannon P, Yang X, Szabolcs MJ, Ravalli S, Sciacca RR, Michler RE: The role of inducible nitric oxide synthase in cardiac allograft rejection. Cardiovasc Res, 1998, 38, 6–15.
8. Carrier M, Pellerin M, Perrault LP, Bouchard D, Page P, Searle N, Lavoie J: Cardioplegic arrest with L-arginine improves myocardial protection: results of a prospective randomized clinical trial. Ann Thorac Surg, 2002, 73, 837–41; discussion 842.
9. Caus T, Desrois M, Izquierdo M, Lan C, LeFur Y, Confort-Gouny S, Metras D et al.: NOS substrate during cardioplegic arrest and cold storage decreases stunning after heart transplantation in a rat model. J Heart Lung Transplant, 2003, 22, 184–191.
10. Chaturvedi RR, Hjortdal VE, Stenbog EV, Ravn HB, White P, Christensen TD, Thomsen AB et al.: Inhibition of nitric oxide synthesis improves left ventricular con-tractility in neonatal pigs late after cardiopulmonary bypass. Heart, 1999, 82, 740–744.
11. Early and six-month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI [angina precoce post-infarto] study). The GISSI-3 APPI Study Group. Am J Cardiol, 1996, 78, 1191–1197.
12. Feelisch M, Schonafinger K, Noack E: Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol, 1992, 44, 1149–1157.
13. Fleming I, Busse R: NO: the primary EDRF. J Mol Cell Cardiol, 1999, 31, 5–14.
14. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, 373–376.
15. Furukawa Y, Matsumori A, Hirozane T, Sasayama S: Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation, 1996, 93, 333–339.
16. Gardiner SM, Kemp PA, March JE, Bennett T: Regional haemodynamic effects of angiotensin II (3–8) in conscious rats. Br J Pharmacol 1993, 110, 159–162.
17. Gottardi R, Szerafin T, Semsroth S: S-nitroso-human serum albumin improves organ preservation in orthotopic heart transplantation in the pig. J Heart Lung Transplantation, 2004, 23, 172, abstr.
18. Grace PA: Ischaemia-reperfusion injury. Br J Surg, 1994, 81, 637–647.
19. Guc MO, Furman BL, Paratt JR: Modification of alpha-adrenoceptor-mediated pressor responses by NG-nitro-L-arginine methyl ester and vasopressin in endotoxin-treated pithed rats. Eur J Pharmacol, 1992, 224, 63–69.
20. Hallstrom S, Gasser H, Neumayer C, Fugl A, Nanobashvili J, Jakubowski A, Huk I et al.: S-nitroso human serum albumin treatment reduces ischemia/reperfusion injury in skeletal muscle via nitric oxide release. Circulation, 2002, 105, 3032–3038.
21. Hartman JC: The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg, 1995, 60, 789–792.
22. Huk I, Nanobashvili J, Neumayer C, Punz A, Mueller M, Afkhampour K, Mittlboeck M et al.: L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation, 1997, 96, 667–675.
23. Iwata A, Sai S, Nitta Y, Chen M, de Fries-Hallstrand R, Dalesandro J, Thomas R et al.: Liposome-mediated gene transfection of endothelial nitric oxide synthase reduces endothelial activation and leukocyte infiltration in transplanted hearts. Circulation, 2001, 103, 2753–2759.
24. Jahania MS, Sanchez JA, Narayan P, Lasley RD, Mentzer RMJ: Heart preservation for transplantation: principles and strategies. Ann Thorac Surg, 1999, 68, 1983–1987.
25. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM et al.: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation, 2004, 109, 172–177.
26. Kitakaze M, Minamino T, Node K, Komamura K, Shino-zaki Y, Mori H, Kosaka H et al.: Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation, 1995, 92, 950–961.
27. Knowles RG, Salter M, Brooks SL, Moncada S: Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun, 1990, 172, 1042–1048.
28. Konorev EA, Joseph J, Tarpey MM, Kalyanaraman B: The mechanism of cardioprotection by S-nitrosoglutathione monoethyl ester in rat isolated heart during cardioplegic ischaemic arrest. Br J Pharmacol, 1996, 119, 511–518.
29. Korn P, Kroner A, Schirnhofer J, Hallstrom S, Bernecker O, Mallinger R, Franz M et al.: Quinaprilat during cardioplegic arrest in the rabbit to prevent ischemia-reperfusion injury. J Thorac Cardiovasc Surg, 2002, 124, 352–360.
30. Korthuis RJ, Granger DN, Townsley MI, Taylor AE: The role of oxygen-derived free radicals in ischemia-induced increases in canine skeletal muscle vascular permeability. Circ Res, 1985, 57, 599–609.
31. Kupatt C, Habazettl H, Zahler S, Weber C, Becker BF, Messmer K, Gerlach E: ACE-inhibition prevents postischemic coronary leukocyte adhesion and leukocyte-dependent reperfusion injury. Cardiovasc Res, 1997, 36, 386–395.
32. Langford EJ, Brown AS, Wainwright RJ, de Belder AJ, Thomas MR, Smith RE, Radomski MW et al.: Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet, 1994, 344, 1458–1460.
33. Lazar HL, Volpe C, Bao Y, Rivers S, Vita JA, Keaney JFJ: Beneficial effects of angiotensin-converting enzyme inhibitors during acute revascularization. Ann Thorac Surg, 1998, 66, 487–492.
34. Lou H, Kodama T, Wang YN, Katz N, Ramwell P, Foegh ML: L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6. J Heart Lung Transplant, 1996, 15, 1248–1257.
35. Mayers I, Salas E, Hurst T, Johnson D, Radomski MW: Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by s-nitrosoglutathione. J Thorac Cardiovasc Surg, 1999, 117, 1009–1016.
36. Murrell W: Nitroglycerine as a remedy for angina pectoris. Lancet 1879, 1, 80–81, 113–115, 151–152, 225–227.
37. Parolari A, Rubini P, Cannata A, Bonati L, Alamanni F, Tremoli E, Biglioli P: Endothelial damage during myocardial preservation and storage. Ann Thorac Surg, 2002, 73, 682–690.
38. Perrault LP, Malo O, Bidouard JP, Villeneuve N, Vilaine JP, Vanhoutte PM: Inhibiting the NO pathway with intra-coronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation. J Heart Lung Transplant, 2003, 22, 439–451.
39. Perrault LP, Nickner C, Desjardins N, Dumont E, Thai P, Carrier M: Improved preservation of coronary endothelial function with Celsior compared with blood and crys-talloid solutions in heart transplantation. J Heart Lung Transplant, 2001, 20, 549–558.
40. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P: Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res, 1994, 28, 34–39.
41. Pieper GM, Cooper M, Johnson CP, Adams MB, Felix CC, Roza AM: Reduction of myocardial nitrosyl complex formation by a nitric oxide scavenger prolongs car-diac allograft survival. J Cardiovasc Pharmacol, 2000, 35, 114–120.
42. Pieper GM, Roza AM, Adams MB, Hilton G, Johnson M, Felix CC, Kampalath B et al.: A ruthenium (III) polyaminocarboxylate complex, a novel nitric oxide scavenger, enhances graft survival and decreases nitrosy-lated heme protein in models of acute and delayed cardiac transplant rejection. J Cardiovasc Pharmacol, 2002, 39, 441–448.
43. Pinsky DJ: The vascular biology of heart and lung preservation for transplantation. Thromb Haemost, 1995, 74, 58–65.
44. Pinsky DJ, Oz MC, Koga S, Taha Z, Broekman MJ, Marcus AJ, Liao H et al.: Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Invest, 1994, 93, 2291–2297.
45. Podesser BK, Schirnhofer J, Bernecker OY, Kroner A, Franz M, Semsroth S, Fellner B et al.: Optimizing ischemia/reperfusion in the failing rat heart-improved myocardial protection with acute ACE inhibition. Circulation, 2002, 106, I277–1283.
46. Radomski MW, Palmer RM, Moncada S: Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA, 1990, 87, 10043–10047.
47. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S: Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res, 1993, 27, 1380–1382.
48. Redondo J, Manso AM, Pacheco ME, Hernandez L, Sa-laices M, Marin J: Hypothermic storage of coronary endothelial cells reduces nitric oxide synthase activity and expression. Cryobiology, 2000, 41, 292–300.
49. Rees DD, Cellek S, Palmer RM, Moncada S: Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun, 1990, 173, 541–547.
50. Roza AM, Cooper M, Pieper G et al.: NOX 100, a nitric oxide scavenger, enhances cardiac allograft survival and promotes long-term graft acceptance. Transplantation, 2000, 69, 227–231.
51. Russell ME, Wallace AF, Wyner LR, Newell JB, Kar-novsky MJ: Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation, 1995, 92, 457–464.
52. Semsroth S, Franz M, Fellner B: Nitric oxide substitution during ischemia/reperfusion improves hemodynamic and metabolic outcome of explanted rabbit hearts after long term ischemia. J Heart Lung Transplantation, 2002, 21, 136, abstr.
53. Shiraishi Y, Lee JR, Laks H, Waters PF, Meneshian A, Blitz A, Johnson K et al.: L-arginine administration dur-ing reperfusion improves pulmonary function. Ann Thorac Surg, 1996, 62, 1580–1587.
54. Shukla N, Angelini GD, Ascione R, Talpahewa S, Ca-poun R, Jeremy JY: Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure. Ann Thorac Surg 2003, 75, 1437–1442.
55. Smith RE, Palmer RM, Moncada S: Coronary vasodila-tation induced by endotoxin in the rabbit isolated per-fused heart is nitric oxide-dependent and inhibited by dexamethasone. Br J Pharmacol, 1991, 104, 5–6.
56. Soto PF, Jia CX, Rabkin DG, Hart JP, Carter YM, Sardo MJ, Hsu DT et al.: Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition. J Thorac Cardiovasc Surg, 2000, 120, 39–46.
57. Southard JH, Belzer FO: Organ preservation. Annu Rev Med, 1995, 46, 235–247.
58. Sternbergh WC, Makhoul RG, Adelman B: Nitric oxide-mediated, endothelium-dependent vasodilation is selectively attenuated in the postischemic extremity. Surgery, 1993, 114, 960–967.
59. Stobierska-Dzierzek B, Awad H, Michler RE: The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001, 38, 923–931.
60. Szabolcs MJ, Sun J, Ma N, Albala A, Sciacca RR, Philips GB, Parkinson J et al.: Effects of selective inhibitors of nitric oxide synthase-2 dimerization on acute cardiac allograft rejection. Circulation, 2002, 106, 2392–2396.
61. Takano H, Tang XL, Qiu Y, Guo Y, French BA, Bolli R: Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. Circ Res, 1998, 83, 73–84.
62. Tsao PS, Aoki N, Lefer DJ, Johnson Gr, Lefer AM: Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation, 1990, 82, 1402–1412.
63. Valantine HA: Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant “atheroma”. Transplantation, 2003, 76, 891–899.
64. Wang T, El Kebir D, Blaise G: Inhaled nitric oxide in 2003: a review of its mechanisms of action. Can J An-aesth, 2003, 50, 839–846.
65. Weis M, Cooke JP: Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol, 2003, 23, 567–575.
66. Wheeldon D, Sharples L, Wallwork J, English T: Donor heart preservation survey. J Heart Lung Transplant 1992, 11, 986–993.